CARM — Carisma Therapeutics Income Statement
0.000.00%
- $45.70m
- -$8.56m
- $14.92m
Annual income statement for Carisma Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 11.2 | 26.5 | 40 | 14.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 108 | 32.3 | 35.1 | 65.9 | 104 |
Operating Profit | -108 | -21.1 | -8.55 | -25.9 | -88.7 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -108 | -21 | -8.61 | -23.8 | -86.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -108 | -22.4 | -0.336 | -19.9 | -86.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -108 | -22.4 | -0.336 | -19.9 | -86.9 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -108 | -22.5 | -0.336 | -19.9 | -86.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -23.6 | -3.81 | 2.62 | 0.579 | -2.59 |
Special Dividends per Share |